Current price (August 6, 2026): $2.96
12-month price target: $9.00
Potential upside: Approximately 204%
Niagen Bioscience is a biotechnology company focused on developing and commercializing products that support cellular health and healthy longevity. Its products are based on the company’s proprietary nicotinamide-riboside molecule.
Investment Thesis
The investment case is supported by rising global interest in extending healthspan, the proliferation of weight-management products, and growing demand for solutions that support metabolism and cellular energy.
A key growth driver is the rapid expansion of the ingredients business, particularly the Niagen Plus line of injectable products.
The launch of a telemedicine platform could broaden access to at-home treatment and support further business growth.
The company’s extensive patent portfolio protects its core technologies and provides optionality to expand into pharmaceutical and clinical business lines.
Niagen is already profitable and consistently generates free cash flow, with room to scale further.
Key Catalysts

• Continued expansion of the ingredients business
  
• Growth of the Niagen Plus injectable-product line
  
• Launch and adoption of the telemedicine platform
  
• Broader access to at-home treatment
  
• Potential expansion into pharmaceutical and clinical business lines
  

Key Risks

• Potential tightening of dietary-supplement regulation
  
• Price competition from lower-cost alternatives
  
• Uncertainty related to legal proceedings in the industry
  

Conclusion: Our 12-month price target is $9 per share, representing approximately 204% potential upside from the current price of $2.96.